TY - JOUR
T1 - Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
AU - Yates, Nicole L.
AU - Liao, Hua Xin
AU - Fong, Youyi
AU - DeCamp, Allan
AU - Vandergrift, Nathan A.
AU - Williams, William T.
AU - Alam, S. Munir
AU - Ferrari, Guido
AU - Yang, Zhi Yong
AU - Seaton, Kelly E.
AU - Berman, Phillip W.
AU - Alpert, Michael D.
AU - Evans, David T.
AU - O'Connell, Robert J.
AU - Francis, Donald
AU - Sinangil, Faruk
AU - Lee, Carter
AU - Nitayaphan, Sorachai
AU - Rerks-Ngarm, Supachai
AU - Kaewkungwal, Jaranit
AU - Pitisuttithum, Punnee
AU - Tartaglia, James
AU - Pinter, Abraham
AU - Zolla-Pazner, Susan
AU - Gilbert, Peter B.
AU - Nabel, Gary J.
AU - Michael, Nelson L.
AU - Kim, Jerome H.
AU - Montefiori, David C.
AU - Haynes, Barton F.
AU - Tomaras, Georgia D.
PY - 2014/3/19
Y1 - 2014/3/19
N2 - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.
AB - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.
UR - http://www.scopus.com/inward/record.url?scp=84899087118&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3007730
DO - 10.1126/scitranslmed.3007730
M3 - Article
C2 - 24648342
AN - SCOPUS:84899087118
SN - 1946-6234
VL - 6
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 228
M1 - 228ra39
ER -